Atlas Trials

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

Clinical trial NCT04961632 · UNKNOWN

Trial details

NCT number
NCT04961632
Sponsor
National Cancer Centre, Singapore
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2020-12-23
Primary completion
2025-11-01
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.